Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept

BACKGROUND: Patients in clinical practice are transitioned from originator etanercept (OR-ETA) to biosimilar etanercept (BS-ETA), but some subsequently retransition. Insights into the incidence of and reasons for retransitioning and the characteristics of these patients could help clinicians success...

Descripción completa

Detalles Bibliográficos
Autores principales: Meijboom, Rosanne W., Gardarsdottir, Helga, Becker, Matthijs L., ten Wolde, Saskia, Egberts, Toine C. G., Giezen, Thijs J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613120/
https://www.ncbi.nlm.nih.gov/pubmed/34704199
http://dx.doi.org/10.1007/s40259-021-00501-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613120/
https://www.ncbi.nlm.nih.gov/pubmed/34704199
http://dx.doi.org/10.1007/s40259-021-00501-x

Ejemplares similares